Combination Therapy for p53 WT Tumors via MDM2 and CK1α Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for p53 wild type tumors, particularly Merkel cell carcinoma, are inadequate due to the functional inactivation of p53 by MDM2 and MDM4, which are overexpressed and regulated by Casein Kinase 1 alpha (CK1α), leading to aggressive cancer progression.
Innovation Solution
Combining an MDM2 inhibitor, such as HDM201, with a CK1α degrading agent like lenalidomide, and/or an MDM4 inhibitor to target and inhibit the p53 pathway, thereby restoring p53 activity and inducing apoptosis in p53 wild type tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MDM2 and MDM4 inhibitors are used to treat p53 WT tumors, then p53 activity is restored and anti-cancer effects are improved, but toxicity increases and higher dosages are required
Solution Approach 1:
The patent segments the p53 inhibition mechanism into two distinct targets: MDM2 and MDM4. By using combination therapy with both an MDM2 inhibitor and an MDM4 inhibitor, the treatment addresses the redundant p53 suppression pathways separately, allowing for more precise and effective restoration of p53 activity while potentially reducing the dosage required for each individual agent, thereby mitigating toxicity.
2Reliability
If MDM2 and MDM4 inhibitors are used to treat p53 WT tumors, then p53 activity is restored, but the treatment complexity increases
Solution Approach 1:
The patent merges two inhibition strategies (MDM2 inhibition and MDM4 inhibition) into a unified combination therapy regimen. This approach addresses the complexity of redundant p53 suppression mechanisms by simultaneously targeting both pathways, ensuring comprehensive restoration of p53 activity while managing treatment complexity through a coordinated dual-agent protocol.
3Reliability
If CK1α is inhibited to reduce MDM4 activity, then p53 function is enhanced, but additional therapeutic agents are required
Solution Approach 1:
The patent introduces CK1α inhibition as an intermediary mechanism to indirectly reduce MDM4 activity. CK1α acts as a mediator that, when inhibited, prevents the phosphorylation and stabilization of MDM4, thereby reducing MDM4 levels and enhancing p53 function. This intermediary approach provides an additional layer of control over the p53 pathway without requiring direct MDM4 targeting.
Data Source
AI summary
The present invention relates to methods of treating p53 wild type (WT) tumors. In particular, the invention provides novel therapies for p53 WT tumors based on the combination of Mouse Double Minute 2 (MDM2) inhibitors, e.g. HDM201, together with Casein Kinase 1 alpha (CK1α) degrading agents and/or an MDM4 inhibitors, e.g. lenalidomide. The combination may be used in the treatment of solid as well as hematologic p53 WT tumors, e.g. Merkel cell carcinoma (MCC) or myelodysplastic syndrome (MDS).